PHA-739358 for the Treatment of Multiple Myeloma

An Exploratory Phase II Study of PHA-739358 in Patients With Multiple Myeloma Harbouring the t(4;14) Translocation With or Without FGFR3 Expression

Status

Terminated

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00872300

Enrollment

Registered

2009-03-31

Start date

2008-10-31

Completion date

2010-09-30

Last updated

2014-05-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Myeloma

Brief summary

The purpose of this study is to determine the antitumor activity of PHA-739358 as single agent IV infusion in adult patients with Multiple Myeloma who have a history of at least 2 previous lines of treatment for the disease.

Interventions

DRUGPHA-739358

Weekly IV infusion for 3 consecutive weeks in a 4-week cycle

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

SUPPORTIVE_CARE

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

* active multiple myeloma progressing after at least 2 prior lines of treatment * measurable disease * t(4;14) translocation * life expectancy of at least 3 months

Exclusion criteria

* uncontrolled hypertension * myocardial infarction, unstable angina, symptomatic congestive heart failure, cerebrovascular accident in the past 6 months. * pregnancy or breast feeding * active infections, including HIV

Design outcomes

Primary

Measure	Time frame
Response Rate according to International Myeloma Working Group uniform response criteria for multiple myeloma.	At end of each cycle

Secondary

Measure	Time frame
Overall safety profile	All cycles

Countries

France, United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026